Efficacy of cefepime and imipenem in experimental murine pneumonia caused by porin-deficient Klebsiella pneumoniae producing CMY-2 β-lactamase

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3311-3316

  Pichardo, Cristina ^a,c   Rodríguez Martínez, José Manuel ^c   Pachón Ibañez, María E ^a   Conejo, Carmen ^c   Ibáñez Martínez, José ^b   Martínez Martínez, Luis ^b,c,d   Pachón, Jerónimo ^a,c   Pascual, Álvaro ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c UNIVERSITY OF SEVILLE   (Spain)

^d HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AZTREONAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFEPIME; CEFPIROME; CEPHALOSPORIN DERIVATIVE; CEPHAMYCIN; CILASTATIN PLUS IMIPENEM; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; PORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG HALF LIFE; FEMALE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PLASMID; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; IMIPENEM; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICE, INBRED C57BL; MICROBIAL SENSITIVITY TESTS; PNEUMONIA, BACTERIAL; PORINS; TREATMENT OUTCOME;

EID: 23044468155     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3311-3316.2005     Document Type: Article

References (33)

1. Alvarez, M., J. H. Tran, N. Chow, and G. A. Jacoby. 2004. Epidemiology of conjugative plasmid-mediated AmpC beta-lactamases in the United States. Antimicrob. Agents Chemother. 48:533-537.
2. Barbhaiya, R. H., S. T. Forgue, and C. R. Gleason. 1992. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob. Agents Chemother. 36:552-557.
3. Barlow, M., and B. G. Hall. 2003. Experimental prediction of evolution of cefepime resistance from the CMY-2 AmpC β-lactamase. Genetics 164:23-29.
4. Bauernfeind, A., Y. Chong, and S. Schweighart. 1989. Extended broad spectrum β-lactamase in Klebsiella pneumonias including resistance to cephamycins. Infection 17:316-321.
5. Bradford, P. A., C. Urban, N. Mariano, S. J. Projan, J. J. Rahal, and K. Bush. 1997. Imipenem resistance in Klebsiella pneumoniae is associated with the combination of ACT-1, a plasmid-mediated AmpC β-lactamase, and the loss of an outer membrane protein. Antimicrob. Agents Chemother. 41:563-569.
6. Cao, V. T., G. Arlet, B. M. Ericsson, A. Tammelin, P. Courvalin, and T. Lambert. 2000. Emergence of imipenem resistance in Klebsiella pneumoniae owing to combination of plasmid-mediated CMY-4 and permeability alteration. J. Antimicrob. Chemother. 46:895-900.
7. Craig, W. A., and S. Gudmunsson. 1991. Postantibiotic effect, p. 403-431. In V. Lorian (ed.), Antibiotics in medicine, 3rd ed. Williams and Wilkins, Baltimore, Md.
8. Esposito, A. L., and J. E. Pennington. 1983. Effect of aging on antibacterial mechanisms in experimental pneumonia. Am. Rev. Respir. Dis. 128:662-667.
9. Fridmodt-Moller, N., M. W. Bentzon, and V. F. Thorasen. 1986. Experimental infection with Streptococcus pneumoniae in mice: correlation of in vitro activity and pharmacokinetic parameters with in vivo effect for 14 cephalosporins. J. Infect. Dis. 154:511-517.
10. Gazouli, M., L. S. Tzouvelekis, E. Prinarakis, V. Miriagou, and E. Tzelepi. 1996. Transferable cefoxitin resistance in enterobacteria from Greek hospitals and characterization of a plasmid-mediated group 1 β-lactamase (LAT-2). Antimicrob. Agents Chemother. 40:1736-1740.
11. González-Leiza, M., J. C. Pérez-Díaz, J. Ayala, J. M. Casellas, J. Martinez-Beltrán, K. Bush, and F. Baquero. 1994. Gene sequence and biochemical characterization of FOX-1 from Klebsiella pneumoniae, a new AmpC-type plasmid mediated β-lactamase with two molecular variants. Antimicrob. Agents Chemother. 38:2150-2157.
12. Horii, T., Y. Arakawa, M. Ohta, S. Ichiyaraa, R. Wacharotayankun, and N. Kato. 1993. Plasmid-mediated AmpC-type β-Lactamase isolated from Klebsiella pneumoniae confers resistance to broad spectrum β-lactams, including moxalactam. Antimicrob. Agents Chemother. 37:984-990.
13. Jacoby, G. A. 1994. Genetics of extended-spectrum beta-lactamases. Eur. J. Clin. Microbiol. Infect. Dis. 13(Suppl. 1):2-11.
14. Jacoby, G. A., and A. A. Medeiros. 1991. More extended-spectrum β-lactamases. Antimicrob. Agents Chemother. 35:1697-1704.
15. Levesque, R., P. H. Roy, R. Letarte, and J. C. Pechère. 1982. A plasmid-mediated cephalosporinase from Achromobacter species. J. Infect. Dis. 145: 753-761.
16. Lewis, K. 2000. Programmed death in bacteria. Microbiol. Mol. Biol. Rev. 64:503-514.
17. Limaye, A. P., R. K. Glautom, D. Black, and T. R. Fritsch. 1997. Rapid emergence of resistance to cefepime during treatment. Clin. Infect. Dis. 25:339-340.
18. Livermore, D. M. 1995. β-Lactamases in laboratory and clinical resistance. Clin. Microbiol. Rev. 8:557-584.
19. MacKenzie, F. M., and I. M. Gould. 1993. The post-antibiotic effect. J. Antimicrob. Chemother. 32:519-537.
20. Martínez-Martínez, L., A. Pascual, S. Hernández- Allés, D. Alvarez-Díaz, A. I. Suárez, J. Tran, V. J. Benedí, and G. A. Jacoby. 1999. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob. Agents Chemother. 43:1669-1673.
21. Martínez-Martínez, L., A. Pascual, and G. A. Jacoby. 1998. Quinolone resistance from a transferable plasmid. Lancet 351:797-799.
22. Medeiros, A. 1997. Evolution and dissemination of β-lactamases accelerated by generations of β-lactam antibiotics. Clin. Infect. Dis. 24:S19-S45.
23. Medeiros, A. A. 1997. Editorial response: relapsing infections due to Enterobacter species: lessons of heterogeneity. Clin. Infect. Dis. 25:341-342.
24. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution susceptibility tests for bacteria that grow aerobically. Fourth edition. Approved Standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
25. National Committee for Clinical Laboratory Standards. 1997. Performance standards for antimicrobial disk susceptibility tests-sixth edition; approved standard. NCCLS document M2-A6. National Committee for Clinical Laboratory Standards, Wayne, Pa.
26. Papanicolaou, G. A., A. A. Medeiros, and G. A. Jacoby. 1990. Novel plasmid-mediated β-lactamase (MIR-1) conferring resistance to oxyimino- and α-methoxy β-lactams in clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 34:2200-2209.
27. Philippen, A., G. Arlet, and G. A. Jacoby. 2002. Plasmid-determined AmpC-type β-lactamases. Antimicrob. Agents Chemother. 46:1-11.
28. Queenan, A. M., S. Jenkins, and K. Bush. 2001. Cloning and biochemical characterization of FOX-5, an AmpC-type plasmid-encoded β-lactamase from a New York City Klebsiella pneumoniae clinical isolate. Antimicrob. Agents Chemother. 45:3189-3194.
29. Rodríguez-Hernández, M. J., J. Pachón, C. Pichardo, L. Cuberos, J. Ibánẽz-Martínez, A. García-Curiel, F. J. Caballero, I. Moreno, and M. E. Jiménez-Mejías. 2000. Imipenem, doxycycline and amikacin in monotherapy and in combination in Acinetobacter baumannii experimental pneumonia. J. Antimicrob. Chemother. 45:493-501.
30. Sanders, C. C. 1987. Chromosomal cephalosporinases responsible for multiple resistance to newer β-lactam antibiotics. Annu. Rev. Microbiol. 41:573-593.
31. Sanders, C. C. 1992. β-Lactamases of gram-negative bacteria: new challenges for new drugs. Clin. Infect. Dis. 14:1089-1099.
32. Shumaker, R. C. 1986. PKCALC: a basic interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metabol. Res. 17:331-348.
33. Stapleton, P. D., K. P. Shannon, and G. L. French. 1999. Carbapenem resistance in Escherichia coli associated with plasmid-determined CMY-4 β-lactamase production and loss of an outer membrane protein. Antimicrob. Agents Chemother. 43:1206-1210.